摘要:
Provided are processes for the purification of a pure rosuvastatin intermediate by thin film evaporation and chemical method, and conversion of the intermediate to rosuvastatin or salts thereof.
摘要:
Provided are processes for the purification of a pure rosuvastatin intermediate by thin film evaporation and chemical method, and conversion of the intermediate to rosuvastatin or salts thereof.
摘要:
The invention encompasses amorphous montelukast sodium having less than about 50 ppm heptane or less than about 100 ppm hexane, less than about 150 ppm toluene, and less than about 2500 ppm C1-C5 alcohols, as well as processes for its preparation.
摘要翻译:本发明包括具有小于约50ppm庚烷或小于约100ppm己烷,小于约150ppm甲苯和小于约2500ppm C 1 -C 5的非晶孟鲁司特钠, 醇,以及其制备方法。
摘要:
Provided are candesartan cilexetil forms and methods of their preparation. Also provided are pharmaceutical compositions prepared by combining at least one pharmaceutically-acceptable excipient with at least one candesartan cilexetil form of the invention.
摘要:
Provided are candesartan cilexetil forms and methods of their preparation. Also provided are pharmaceutical compositions prepared by combining at least one pharmaceutically-acceptable execipient with at least one candesartan cilexetil form of the invention.
摘要:
A process for preparing candesartan cilexetil comprising heating a solution of trityl candesartan cilexetil in a water immiscible solvent in the presence of at least one C1-C4 alcohol and a first portion of water; combining the solution with a second portion of water to obtain a two-phase system; and recovering candesartan cilexetil.
摘要:
Provided are candesartan cilexetil forms and methods of their preparation. Also provided are pharmaceutical compositions prepared by combining at least one pharmaceutically-acceptable excipient with at least one candesartan cilexetil form of the invention.